Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
Rapport Therapeutics reported robust Phase 2a follow-up data for RAP-219, showing a 90% median reduction in clinical seizures over baseline and an updated 22-day half-life, supporting the planned Phase 3 initiation in Q2 2026. The company accelerated its Bipolar Mania Phase 2 topline timeline to Q4 2026 and signed a strategic collaboration with Tenacia Biotechnology, which contributed $20.0 million in Q1 revenue.
Key figures
- Revenue
- $20.0 million
- Drug Name
- RAP-219
- Guidance
- Phase 2 bipolar mania topline results expected Q4 2026 (accelerated from 1H 2027); Phase 3 FOS initiation on track for Q2 2026
- Phase Of Trial
- Phase 2a
- Runway
- into second half of 2029
- Net loss
- $19.9 million
- Half life
- 22 days
- Cash position
- $476.8 million
- Seizure reduction
- 90% median reduction in clinical seizures (weeks 9-12)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.